New approach to cancer therapy: Heparin binding-epidermal growth factor-like growth factor as a novel targeting molecule

Shingo Miyamoto, Hiroshi Yagi, Fusanori Yotsumoto, Shinji Horiuchi, Toshiyuki Yoshizato, Tatsuhiko Kawarabayashi, Masahide Kuroki, Eisuke Mekada

研究成果: ジャーナルへの寄稿学術誌査読

30 被引用数 (Scopus)

抄録

Heparin binding-epidermal growth factor-like growth factor (HB-EGF) is one of the EGF receptor ligands and possesses several functional domains. It is involved in diverse biological processes, including wound healing, blast implantation, atherosclerosis and tumor formation, through its interactions with various molecules. We have reported that HB-EGF gene expression is significantly elevated in human ovarian cancer, and further demonstrated that HB-EGF plays key roles in the acquisition of malignant phenotypes, such as cell survival in peritoneal fluid, cell adhesion on extracellular matrices, invasion, angiogenesis, tumorigenicity, and chemoresistance in ovarian cancer. Thus, HB-EGF was considered as a promising target for cancer therapy. In vitro as well as in vivo experiments have revealed that cross-reacting material 197 (CRM197), a specific inhibitor of HB-EGF, or a small interfering RNA for HB-EGF can block each step involved in peritoneal dissemination. According to these pieces of evidence, the development of targeting tools against HB-EGF, such as CRM197, could allow us to improve the prognosis of cancer patients.

本文言語英語
ページ(範囲)3713-3721
ページ数9
ジャーナルAnticancer research
27
6 A
出版ステータス出版済み - 11月 2007

!!!All Science Journal Classification (ASJC) codes

  • 腫瘍学
  • 癌研究

フィンガープリント

「New approach to cancer therapy: Heparin binding-epidermal growth factor-like growth factor as a novel targeting molecule」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル